Israeli ADHD drug developer Alcobra increases proposed IPO deal size to $25mm


Shutterstock photo

Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised the proposed deal size for its upcoming IPO on Wednesday. The Tel Aviv, Israel-based company now plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. The company had previously filed to offer 1.4 million shares at the same range. At the midpoint of the revised terms, Alcobra will raise 67% greater proceeds than previously anticipated. 

Alcobra, which was founded in 2008 and is yet to generate any revenue, plans to list on the NASDAQ under the symbol ADHD. Aegis Capital is the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by